Anti-SLC18A1 monoclonal antibody

Pre-made anti-SLC18A1 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SLC18A1/SLC18A1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1657-Ab-1/ GM-Tg-hg-IP1657-Ab-2Anti-Human SLC18A1 monoclonal antibodyHuman
GM-Tg-rg-IP1657-Ab-1/ GM-Tg-rg-IP1657-Ab-2Anti-Rat SLC18A1 monoclonal antibodyRat
GM-Tg-mg-IP1657-Ab-1/ GM-Tg-mg-IP1657-Ab-2Anti-Mouse SLC18A1 monoclonal antibodyMouse
GM-Tg-cynog-IP1657-Ab-1/ GM-Tg-cynog-IP1657-Ab-2Anti-Cynomolgus/ Rhesus macaque SLC18A1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1657-Ab-1/ GM-Tg-felg-IP1657-Ab-2Anti-Feline SLC18A1 monoclonal antibodyFeline
GM-Tg-cang-IP1657-Ab-1/ GM-Tg-cang-IP1657-Ab-2Anti-Canine SLC18A1 monoclonal antibodyCanine
GM-Tg-bovg-IP1657-Ab-1/ GM-Tg-bovg-IP1657-Ab-2Anti-Bovine SLC18A1 monoclonal antibodyBovine
GM-Tg-equg-IP1657-Ab-1/ GM-Tg-equg-IP1657-Ab-2Anti-Equine SLC18A1 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1657-Ab-1/ GM-Tg-hg-IP1657-Ab-2; GM-Tg-rg-IP1657-Ab-1/ GM-Tg-rg-IP1657-Ab-2;
GM-Tg-mg-IP1657-Ab-1/ GM-Tg-mg-IP1657-Ab-2; GM-Tg-cynog-IP1657-Ab-1/ GM-Tg-cynog-IP1657-Ab-2;
GM-Tg-felg-IP1657-Ab-1/ GM-Tg-felg-IP1657-Ab-2; GM-Tg-cang-IP1657-Ab-1/ GM-Tg-cang-IP1657-Ab-2;
GM-Tg-bovg-IP1657-Ab-1/ GM-Tg-bovg-IP1657-Ab-2; GM-Tg-equg-IP1657-Ab-1/ GM-Tg-equg-IP1657-Ab-2
Products NameAnti-SLC18A1 monoclonal antibody
Formatmab
Target NameSLC18A1
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SLC18A1 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1657-Ag-1Recombinant multi-species VMAT1/ SLC18A1/ CGAT protein


    Target information

    Target IDGM-IP1657
    Target NameSLC18A1
    Gene ID6570,110877,25693,705489,486138,101094843,617708,100055485
    Gene Symbol and Synonyms4832416I10Rik,CGAT,SLC18A1,VAT1,VMAT-1,VMAT1
    Uniprot AccessionP54219,Q01818
    Uniprot Entry NameVMAT1_HUMAN,VMAT1_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000036565
    Target ClassificationN/A

    The target: SLC18A1, gene name: SLC18A1, also named as CGAT, VAT1, VMAT1. The vesicular monoamine transporter acts to accumulate cytosolic monoamines into vesicles, using the proton gradient maintained across the vesicular membrane. Its proper function is essential to the correct activity of the monoaminergic systems that have been implicated in several human neuropsychiatric disorders. The transporter is a site of action of important drugs, including reserpine and tetrabenazine (Peter et al., 1993 [PubMed 7905859]). See also SLC18A2 (MIM 193001).[supplied by OMIM, Mar 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.